BioCentury | Jan 16, 2012
Financial News

Syndexa completes venture financing

Syndexa Pharmaceuticals Corp. , Cambridge, Mass. Business: Endocrine/Metabolic, Cardiovascular Date completed: 1/5/12 Type: Venture financing Raised: $8.5 million Investor: MP Healthcare Venture Management Note: The financing is a series B-1 round. WIR Staff Cardiovascular...
BioCentury | May 10, 2010
Company News

FoldRx board of directors update

...Cardiovascular, Neurology Appointed: Georges Gemayel as executive chairman, currently a director of Adolor Corp. and Syndexa Pharmaceuticals Corp. WIR...
BioCentury | Oct 30, 2008
Distillery Therapeutics

Indication: Endocrine disease

...the role of the JNK docking site in indications such as melanoma, stroke and asthma. Syndexa Pharmaceuticals Corp....
BioCentury | Oct 30, 2008
Targets & Mechanisms

Block JNK at the dock

...a new strategy for selective targeting of protein kinases. Teo Uysal, president and CEO of Syndexa Pharmaceuticals Corp....
...desired activity in cell- and animal-based assays." He also noted that findings were consistent with Syndexa's...
...that established a role for chronic JNK activation in diabetes, obesity and low-grade inflammatory responses. Syndexa...
BioCentury | Aug 11, 2008
Company News

Syndexa board of directors update

Syndexa Pharmaceuticals Corp. , Cambridge, Mass. Business: Endocrine, Cardiovascular Appointed: Georges Gemayel, CEO of Altus Pharmaceuticals Inc. WIR Staff Cardiovascular...
BioCentury | Jun 2, 2008
Company News

Syndexa board of directors update

Syndexa Pharmaceuticals Corp. , Cambridge, Mass. Business: Endocrine, Cardiovascular Appointed: Yalcin Ayasli, founder of Hittite Microwave Corp. WIR Staff...
BioCentury | May 31, 2008
Financial News

Syndexa raises $15 million

...B round led by new and sole investor Yalcin Ayasli, who will join Syndexa's board. Syndexa...
BioCentury | Mar 27, 2008
Distillery Therapeutics

This Week in Therapeutics

...marketing rapamycin derivatives as immunosuppressants for use in organ transplants. Patent application filed; licensed to Syndexa Pharmaceuticals Corp....
BioCentury | Jan 7, 2008
Emerging Company Profile

Corporate Profile

Syndexa Pharmaceuticals Corp. Cambridge, Mass. Technology: Small molecule therapeutics addressing inflammation-related causes of metabolic diseases Disease focus: Metabolic Clinical status: Preclinical Founded: 2005 by Goekhan Hotamisligil, Teo Uysal and Michael Karin University collaborators: Harvard University,...
BioCentury | Jan 7, 2008
Emerging Company Profile

Syndexa: De-stressing diabetes

...as the insulin-sensitizing thiazolidinediones, address the disease's symptoms but have no meaningful impact on progression. Syndexa Pharmaceuticals Corp....
...is thought to play a role in insulin resistance (see BioCentury, Oct. 13, 1997) . Syndexa...
...domain is always going to be difficult, and would necessitate high dosing. As a result, Syndexa...
Items per page:
1 - 10 of 13
BioCentury | Jan 16, 2012
Financial News

Syndexa completes venture financing

Syndexa Pharmaceuticals Corp. , Cambridge, Mass. Business: Endocrine/Metabolic, Cardiovascular Date completed: 1/5/12 Type: Venture financing Raised: $8.5 million Investor: MP Healthcare Venture Management Note: The financing is a series B-1 round. WIR Staff Cardiovascular...
BioCentury | May 10, 2010
Company News

FoldRx board of directors update

...Cardiovascular, Neurology Appointed: Georges Gemayel as executive chairman, currently a director of Adolor Corp. and Syndexa Pharmaceuticals Corp. WIR...
BioCentury | Oct 30, 2008
Distillery Therapeutics

Indication: Endocrine disease

...the role of the JNK docking site in indications such as melanoma, stroke and asthma. Syndexa Pharmaceuticals Corp....
BioCentury | Oct 30, 2008
Targets & Mechanisms

Block JNK at the dock

...a new strategy for selective targeting of protein kinases. Teo Uysal, president and CEO of Syndexa Pharmaceuticals Corp....
...desired activity in cell- and animal-based assays." He also noted that findings were consistent with Syndexa's...
...that established a role for chronic JNK activation in diabetes, obesity and low-grade inflammatory responses. Syndexa...
BioCentury | Aug 11, 2008
Company News

Syndexa board of directors update

Syndexa Pharmaceuticals Corp. , Cambridge, Mass. Business: Endocrine, Cardiovascular Appointed: Georges Gemayel, CEO of Altus Pharmaceuticals Inc. WIR Staff Cardiovascular...
BioCentury | Jun 2, 2008
Company News

Syndexa board of directors update

Syndexa Pharmaceuticals Corp. , Cambridge, Mass. Business: Endocrine, Cardiovascular Appointed: Yalcin Ayasli, founder of Hittite Microwave Corp. WIR Staff...
BioCentury | May 31, 2008
Financial News

Syndexa raises $15 million

...B round led by new and sole investor Yalcin Ayasli, who will join Syndexa's board. Syndexa...
BioCentury | Mar 27, 2008
Distillery Therapeutics

This Week in Therapeutics

...marketing rapamycin derivatives as immunosuppressants for use in organ transplants. Patent application filed; licensed to Syndexa Pharmaceuticals Corp....
BioCentury | Jan 7, 2008
Emerging Company Profile

Corporate Profile

Syndexa Pharmaceuticals Corp. Cambridge, Mass. Technology: Small molecule therapeutics addressing inflammation-related causes of metabolic diseases Disease focus: Metabolic Clinical status: Preclinical Founded: 2005 by Goekhan Hotamisligil, Teo Uysal and Michael Karin University collaborators: Harvard University,...
BioCentury | Jan 7, 2008
Emerging Company Profile

Syndexa: De-stressing diabetes

...as the insulin-sensitizing thiazolidinediones, address the disease's symptoms but have no meaningful impact on progression. Syndexa Pharmaceuticals Corp....
...is thought to play a role in insulin resistance (see BioCentury, Oct. 13, 1997) . Syndexa...
...domain is always going to be difficult, and would necessitate high dosing. As a result, Syndexa...
Items per page:
1 - 10 of 13